Core Viewpoint - Ganli Pharmaceutical showcased its self-developed GLP-1 receptor agonist, Bofanglureptide (GZR18), and insulin formulation GZR4 at the 85th American Diabetes Association (ADA) conference, attracting significant attention in the global metabolic disease community [1] Group 1: Company Performance and Market Position - Ganli Pharmaceutical's performance has significantly reshaped investor expectations, with multiple institutions recognizing it as a leading domestic insulin provider, entering a performance release phase due to price and volume increases from procurement renewals and breakthroughs in innovative pipelines [2][3] - The company achieved a 32.6% overall increase in procurement volume, with its three generations of insulin accounting for 30% of the market, leading to substantial sales growth [4] - The international revenue reached 528 million yuan, a year-on-year increase of 23.89%, demonstrating Ganli's capability in global supply chain and cost efficiency management [5] Group 2: Research and Development - Ganli Pharmaceutical invested 646 million yuan in R&D in 2024, representing 21.2% of its revenue, focusing on metabolic diseases [4] - The II phase clinical results for GZR4 and Bofanglureptide showed significant potential in improving HbA1c levels and weight loss compared to existing treatments, indicating a strong clinical advantage [4][7] Group 3: Competitive Landscape and Market Strategy - The implementation of centralized procurement policies has led to a structural shift in the Chinese insulin market, with Ganli's market share increasing from 19% to 37% [6] - Ganli's pricing strategy positions its insulin products at 70%-80% of the prices of competitors like Novo Nordisk, while demonstrating equivalent efficacy through equivalence studies [6][7] Group 4: Future Outlook and Globalization - If Bofanglureptide successfully enters the market, it could tap into a global obesity treatment market worth $20 billion, highlighting the long-term growth potential for Ganli [2] - Ganli is positioned as a benchmark for Chinese innovative drugs on a global scale, with the potential to capture significant market share in the evolving diabetes treatment landscape [8]

长江商报奔腾新闻记者沈右荣 国产胰岛素"双雄"之一的通化东宝（600867）(600867.SH)预告的业绩再度变脸。 4月27日晚，通化东宝发布2024年年度业绩预告更正公告，公司最新的预告为，2024年，公司实现归属 于母公司股东的净利润(简称"归母净利润")约为亏损4272.32万元，与上年同期相比，将减少约12.11亿 元，同比减少幅度约103.66%；预计实现扣除非经常性损益的净利润(简称"扣非净利润")为亏损919.54万 元，与上年同期相比，将减少约11.77亿元，同比减少约100.79%。 今年1月20日，通化东宝第一次发布2024年度业绩预告。当时，公司预计归母净利润约为4052.77万元， 与上年同期相比，将减少约11.27亿元，同比减少幅度约为96.53%。 对于归母净利润的大幅下降，公司解释，由于新一轮胰岛素集采落地带来公司产品价格下调的普遍预 期，公司商业客户对库存进行控制与调整，对公司发货造成一定影响，因此销售收入同比下滑。为更好 落实胰岛素产品集采相关政策，公司对集采实施前存在于流通环节的全部库存产品，原供货价与集采实 施价格之间的差额进行一次性冲销或返还，导致公司收入减少。 此 ...

长江商报消息 ●长江商报记者 沈右荣 国产胰岛素"双雄"之一的通化东宝（600867.SH）业绩再变脸。 4月27日晚，通化东宝发布业绩预告更正公告。更正后的业绩为，2024年，公司预计实现归属于母公司 股东的净利润（简称"归母净利润"）约为亏损4272.32万元，同比下降103.66%；预计实现扣除非经常性 损益的净利润（简称"扣非净利润"）为亏损919.54万元，同比下降100.79%。 这是通化东宝年内第二次更正2024年度经营业绩预告。 今年1月20日，公司预计归母净利润、扣非净利润均大幅下降，但处于盈利状态。今年2月27日，公司更 正后的业绩，较上年同期进一步下降，此时，仍然是盈利的。 如今，在2024年年度报告披露前夕，通化东宝再度更正业绩预告，归母净利润、扣非净利润均由盈转 亏。 业绩预告频繁更正，涉及研发项目终止、侵权官司败诉、资产转让等多方面因素。其中，因为侵犯商标 权，公司被判赔付6131.21万元。 年度亏损，这还是通化东宝自2005年以来的首次。2023年，通化东宝盈利超过11亿元。 值得一提的是，通化东宝的大股东质押率达95.20%。 年报披露前2天再更正预告 在年度报告披露的前2天 ...